(PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 ) [13] . Importantly, in
shift assays showed that 1f) [11] . By contrast, the expression of SHIP2, a phospho-PPAR␥ is able to bind two response elements in the inositide 5-phosphatase [12] , was not influenced by rosiggenomic sequence upstream of PTEN. Our results litazone (Figure 1f ). This specificity of PPAR␥-mediated demonstrate a role for PPAR␥ in regulating PI upregulation of PTEN is compatible with an exclusive 3-kinase signaling by modulating PTEN expression inhibitory role for the 3-phosphatase pathway of PtdInsP 3 in inflammatory and tumor-derived cells. metabolism, whereas 5-phosphatases, including SHIP2, control the relative levels of two signaling lipids preparations. *p Ͻ 0.05 versus control. PTEN, total PKB (T-PKB), and phosphorylated PKB (P-PKB) protein PKB was apparent, whereas the levels of total PKB protein known subtypes of PPAR, were unchanged ( Figure 2d ). PPAR␦ expression, unlike PPAR␣, was found to increase remained unchanged. These results point to a precise inverse relationship between the level of endogenous exduring monocyte differentiation. PTEN mRNA and protein content, however, were both significantly reduced pression of PTEN and the activity state of the PI 3-kinase pathway, and are compatible with the results of studies by PPAR␥AS, attaining Ͼ95% reduction by day 7 ( Figure  2c,d ). This apparent abolition of PTEN protein levels by involving ectopic overexpression of PTEN in a variety of cells.
PPAR␥AS treatment suggests that PPAR␥ plays a dominant role in the control of this important enzyme in fully differentiated macrophages. To define further the role of PPAR␥ in regulating PTEN expression, antisense oligonucleotides (AS) were used specifically to abolish the increased expression of PPAR␥ The observation that PTEN protein was present in naïve monocytes, when little if any PPAR␥ is present, suggests during monocyte differentiation over a 7 day time course. Cells receiving control oligonucleotides behaved no difan alternative mechanism of control of expression and/or that significant constitutive expression of the PTEN gene ferently to untreated cells (data not shown). PPAR␥AS prevented the upregulation of PPAR␥ mRNA, reaching occurs, as might be expected of such a powerful tumor suppressor. Although levels of PKB were unaffected by around 90% inhibition after 7 days in culture ( Figure  2a ). The dramatic increase in osteopontin mRNA that either differentiation or the presence of PPAR␥AS, the proportion that was phosphorylated dramatically inaccompanied differentiation, however, was not altered by PPAR␥AS (Figure 2b ). These data were corroborated by creased in parallel with the loss of PTEN, demonstrating a clear activation of the PI 3-kinase cascade (Figure 2d ). Western blot analysis demonstrating a selective loss of PPAR␥ protein over 7 days in the presence of PPAR␥AS, This was confirmed by following apoptosis, as measured by cellular caspase 9 activity, which showed a significant while protein levels of PPAR␣ and PPAR␦, the two other Specific PPAR␥ antisense oligonucleotides inhibit macrophage PTEN expression and influence cellular function. Freshly isolated human monocytes received either control (C) or antisense (AS) PPAR␥ oligonucleotides (designed and manufactured by Biognostik, Germany) at a final concentration of 1 M and were incubated in culture for 7 days with medium changes every 2 to 3 days. The sequence lengths of antisense PPAR␥ (sequence ID: 2.01724) and the respective control (sequence ID: 1.02773) were the same, as were their G/C contents. mRNA levels of PPAR␥ (a), osteopontin (b), PTEN (c), and MMP-9 (f) were monitored at days 1, 4, and 7. (d) Western blot analysis of PPAR␥AS-treated macrophages demonstrating changes in PPAR␥, PTEN, and P-PKB protein content but not PPAR␣, PPAR␦, or T-PKB. PPAR␥ antibodies were purchased from Biomol GMBH, while PPAR␣ and PPAR␦ antibodies were purchased from Affinity Bioreagents. (e) PPAR␥AS-mediated decrease in caspase 9 activity at day 7. Caspase activity was measured using a colorimetric apoptosis detection kit (R&D Systems). (g) Enhanced MMP-9 release by PPAR␥AS-treated macrophages. MMP-9 activity assays were performed on cell supernates using an MMP-9 ELISA kit (R&D Systems). Data are means Ϯ SD from at least four different monocyte preparations except for the representative Western blot shown in (d). *p Ͻ 0.05, S versus AS.
reduction of approximately 60% at day 7 in macrophages rosiglitazone influencing the levels of total PKB protein or indeed of p85␣, a subunit of class IA PI 3-kinases [15] . incubated with PPAR␥AS (Figure 2e) . Finally, and in complete contrast to the significant inhibition of macrophage MMP-9 expression by rosiglitazone (Figure 1c) , Taken together, our findings have shed new light on how PPAR␥AS-treated macrophages released significantly a powerful tumor suppressor protein, PTEN, is regulated greater quantities of MMP-9 protein into the culture mewithin cells. Thus far there is little evidence for acute dium, which paralleled a significant increase in mRNA regulation of PTEN via covalent modifications such as levels (Figure 2f,g ). Both experimental designs confirm phosphorylation. Phosphorylation of several residues in a role of PPAR␥ in the regulation of MMP-9.
the C terminus of PTEN, possibly mediated by casein kinase 2, appears to exert only a minor effect on PTEN's activity state, but may instead contribute to the stability To investigate whether the tumor suppressive effects of PPAR␥ agonists in various malignancies might also inof the protein in vivo [16] . Unlike many other enzymes involved in the synthesis and metabolism of inositol lipid volve effects on PTEN, we investigated whether rosiglitazone could influence PTEN levels in two tumor lines, signals, PTEN appears to be constitutively active so that there is a tight inverse relationship between PTEN exCaco2 colorectal cancer cells and MCF7 breast cancer cells. Previous studies have shown other PPAR␥ activators pression levels and the steady state concentration of PtdInsP 3 , together with the signaling pathways downto inhibit proliferation in cultured breast cancer cells [5] . The data in Figure 3 demonstrate that rosiglitazone instream of this bioactive lipid. This idea is consistent with the observation that the inactivation of just one PTEN creased the levels of PTEN protein in parallel to inhibiting significantly the rate of proliferation of both cancer allele has an important consequence on cell survival and proliferation [17] . To confirm further whether PPAR␥ cell lines. Once again, and consistent with our findings in macrophages, the proportion of PKB that was phosphorregulation is direct, we have analyzed the promoter region of the PTEN gene for the presence of peroxisome proliferylated in Caco2 cells decreased in parallel with increasing expression of PTEN (Figure 3b ). This occurred without ator response elements (PPREs). The analysis identified two putative PPAR␥ response elements in 23.3 kb of observed that mice lacking all forms of the PI 3-kinase regulatory subunit, p85␣, were, surprisingly, hypoglycesequence (Figure 4a) . In order to test whether PPAR␥ could bind to these putative PPREs, gel retardation analymic and displayed increased glucose tolerance, which indicated enhanced insulin sensitivity. A substantial reducsis was performed. The data in Figure 4b demonstrate that both PPREs recognize and bind PPAR␥. Transcriptional tion in PI 3-kinase function did not, therefore, result in insulin resistance. Clearly, much is still to be understood regulation of PTEN expression via PPAR␥, therefore, provides a powerful, potentially ubiquitous mechanism about feedback control loops in insulin signaling, but the modulation of the PI 3-kinase cascade through enhanced for the tight regulation of basal and agonist-stimulated components of the PI 3-kinase signaling cascade.
PTEN activity may represent one means of maintaining insulin-stimulated PI 3-kinase activity within physiologically relevant limits. These findings prompt some immediate considerations because the thiazolidinedione PPAR␥ agonists, pioglitazone and rosiglitazone, have recently been introduced An important feature of these new observations is the potential implication for the future treatment of cancers as insulin-sensitizing agents for the treatment of type 2 diabetes. The demonstration that PPAR␥ activation can in which PTEN is still functional, since PPAR␥ agonists may well prove to be effective anti-cancer drugs. Indeed, downregulate PI 3-kinase signaling appears to represent a paradox because this effect would be expected to inhibit an earlier agent, troglitazone, was recently shown to have tumor-differentiating properties [20, 21] . Moreover, the insulin action. Recent findings, however, have indicated that intense or prolonged PI 3-kinase signaling can be upregulation of PTEN and subsequent dampening of the PI 3-kinase pathway in inflammatory cells, such as in detrimental to insulin sensitivity. For example, increased class IA PI 3-kinase function caused insulin resistance in macrophages as demonstrated here, may also explain the beneficial activities of thiazolidinedione PPAR␥ activators 3T3-L1 adipocytes [18] . Binding of PPAR␥-programmed nonprogrammed reticulocyte lysate indicated, reticulocyte lysate alone (lanes 2 and 3, and reticulocyte lysate to the DR1 PPAR synthesized using the ProteinScript II kit 8 and 9, respectively). 5 l of programmed response element from the ApoCIII gene (Ambion), before free and protein-bound DNA lysates was also incubated with a 100-fold promoter is shown in lanes 6 and 12. Proteinwere separated on 6% DNA retardation gels molar excess of PPRE1 (lane 4) or PPRE2
DNA complexes formed are indicated with an (Invitrogen). 
